KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles: 2009-2024

Historic Amortization - Intangibles for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $627.3 million.

  • Jazz Pharmaceuticals' Amortization - Intangibles rose 6.93% to $168.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $639.2 million, marking a year-over-year increase of 3.10%. This contributed to the annual value of $627.3 million for FY2024, which is 3.13% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Amortization - Intangibles of $627.3 million as of FY2024, which was up 3.13% from $608.3 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Amortization - Intangibles high stood at $627.3 million for FY2024, and its period low was $259.6 million during FY2020.
  • In the last 3 years, Jazz Pharmaceuticals' Amortization - Intangibles had a median value of $608.3 million in 2023 and averaged $611.6 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Amortization - Intangibles decreased by 26.84% in 2020, and later spiked by 102.55% in 2021.
  • Jazz Pharmaceuticals' Amortization - Intangibles (Yearly) stood at $259.6 million in 2020, then spiked by 102.55% to $525.8 million in 2021, then rose by 13.96% to $599.2 million in 2022, then grew by 1.52% to $608.3 million in 2023, then increased by 3.13% to $627.3 million in 2024.